Cemiplimab (new indication: non-small cell lung cancer (NSCLC), 1st line)

Subject:

• Active Substance: Cemiplimab
• Name: Libtayo^®
• Therapeutic area: Non-small cell lung cancer (NSCLC)
• Pharmaceutical company: Sanofi-Aventis Deutschland GmbH

Time table:

• Start: 01.08.2021
• Final decision by G-BA: 20.01.2022

Final decision:

• No additional benefit proved